Intra Cellular Therapies | ITCI - Ebit



Ebit Veränderung Datum
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
BioCryst Pharmaceuticals USD -4.51M 12.2M 2024-12
Biogen USD 659.6M 157M 2025-09
Bristol-Myers Squibb USD 3.47B 567M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Esperion Therapeutics USD -16.03M 11.51M 2024-09
Gilead Sciences USD 2.96B 551M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
J&J USD 5.11B 2.3B 2025-12
Minerva Neurosciences USD -4.37M 1.71M 2024-09
Nektar Therapeutics USD -34.34M 3.68M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.48B 343M 2025-09
Prothena USD -39.76M 12.25M 2025-09
RedHill Biopharma USD 2.69M 47.97M 2023-06
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -10.28M 721K 2024-12